<DOC>
	<DOCNO>NCT01675011</DOCNO>
	<brief_summary>This randomize , prospective , multi-center study 225 female subject age 30-50 year symptoms uterine fibroid . All subject follow total thirty-six ( 36 ) month follow uterine fibroid embolization .</brief_summary>
	<brief_title>Embozene Microspheres Uterine Fibroid Embolization ( UFE )</brief_title>
	<detailed_description />
	<mesh_term>Leiomyoma</mesh_term>
	<mesh_term>Myofibroma</mesh_term>
	<criteria>Subject able provide inform consent must sign Institutional Review Board approve Informed Consent Form . Premenopausal woman age 3050 year time enrollment Have select forUterine Fibroid Embolization ( UFE ) prior entry study . Patient history pelvic malignancy Patient abnormal Pap smear within 12 month plan Uterine Fibroid Embolization procedure Patient coexist condition might explain abnormal bleeding ( include endometrial hyperplasia adenomyosis ) pelvic pain ( include endometriosis ovarian cyst ) . Is substantial risk need organ transplantation , renal insufficiency . Patient evidence current recent pelvic inflammatory disease uterine infection . Patient severe contrast allergy renal insufficiency would represent contradiction administration iodinebased contrast agent . Patients unable comply followup requirement study .</criteria>
	<gender>Female</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>